Characterization of impermeability variants of Pseudomonas aeruginosa isolated during unsuccessful therapy of experimental endocarditis.
AUTOR(ES)
Bayer, A S
RESUMO
We characterized five amikacin-resistant variants of Pseudomonas aeruginosa isolated from aortic valve vegetations during unsuccessful therapy of experimental endocarditis. These organisms were cross resistant to other aminoglycosides. No aminoglycoside-modifying enzymes were produced by these strains. However, all five variants demonstrated significant defects in permeability and intracellular uptake of [3H]amikacin when compared with the amikacin-susceptible parental strain (0 to 26% of that of the parental strain; mean, approximately 15%). The permeability defects were unstable in vitro, with normalization after serial passage in antibiotic-free media. The variants grew as nonpigmented, small-colony types, with in vitro generation times approximately 1.5 to 2 times longer than that of the parental strain (30 to 40 versus 20 min, respectively). Two impermeability variants were compared with the parental strain for ability to induce experimental endocarditis in rabbits with aortic catheters. Both variants were virulent in vivo; however, mean bacterial densities in vegetations were approximately 2.5 log10 CFU/g lower in animals challenged with the variants than in animals challenged with the parental strain, probably reflecting a slower in vivo growth rate.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=174654Documentos Relacionados
- Characterization of mechanisms of quinolone resistance in Pseudomonas aeruginosa strains isolated in vitro and in vivo during experimental endocarditis.
- Development of beta-lactam resistance and increased quinolone MICs during therapy of experimental Pseudomonas aeruginosa endocarditis.
- Comparison of ciprofloxacin with azlocillin plus tobramycin in the therapy of experimental Pseudomonas aeruginosa endocarditis.
- Ampicillin therapy of experimental enterococcal endocarditis.
- In vitro studies of investigational beta-lactams as possible therapy for Pseudomonas aeruginosa endocarditis.